Greenwich LifeSciences (Nasdaq: GLSI), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, provided an update on the expansion of the clinical trial into Europe. The Company's application to expand Flamingo-01 into Europe has been reviewed by European Medicines Agency (EMA) through EMA's Clinical Trials Information System (CTIS). The Company was informed that the manufacturing, non-clinical, clinical, statistical, and regulatory sections of its application are acceptable and the regulators' requests for information have been addressed. The regulators have thus approved the clinical trial, marking a major milestone for the Company.

Unusual Machines (NYSE American: UMAC) announced the closing of its acquisitions of Fat Shark Holdings, Ltd. (“Fat Shark”), a pioneer in the design and manufacture of ultra-low latency first-person-view (FPV) goggles, and Rotor Riot LLC (“Rotor Riot”), a curated e-commerce marketplace focused on serving drone enthusiasts. "With the acquisitions of Fat Shark and Rotor Riot, Unusual Machines is well positioned to serve the FPV drone market," said Allan Evans, CEO of Unusual Machines. "These strategic moves provide the basis from which we are able to focus on delivering great products to enthusiasts, drone builders, and FPV pilots."

Better Therapeutics (Nasdaq: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its novel Cognitive Behavioral Therapy (CBT) platform intended to treat adults with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. Breakthrough status is reserved for technologies that demonstrate the potential to be more effective than current standard of care in patients with serious or life-threatening conditions.

Sharps Technology (Nasdaq: STSS), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is preparing to make the first shipment of its 1mL and 3mL Securegard smart safety syringe line to the Latin American healthcare market. The initial product orders have been placed through a collaborative effort between Sharps and a Latin American distribution partner based in Colombia and represent a significant step towards promoting safer healthcare practices in the region. Tapping into the growing interest in safety syringe technology in Latin America, the collaboration will make the Securegard syringe line available to hospitals, pharmacies, and direct points of sale and will give healthcare networks access to utilizing the technology and firsthand experience with its real-world benefits.